Corporate Banner
Satellite Banner
Medicinal Chemistry
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

BioFocus and Ono Sign a Drug Discovery Agreement in the Field of CNS Disorders

Published: Monday, October 08, 2012
Last Updated: Monday, October 08, 2012
Bookmark and Share
BioFocus will use its drug discovery platform to deliver leads and clinical candidates for its client.

Galapagos NV has announced that its service division BioFocus and Ono Pharmaceutical Co., Ltd. (Osaka Japan) have signed a new collaboration agreement, focused on discovering novel drugs in the field of CNS disorders.

Under the new agreement, BioFocus will use its drug discovery platform to deliver leads and clinical candidates for its client. Financial details were undisclosed.

“We are delighted to have this new agreement, which is the first drug discovery program with this, a most valued, client” said Dr. Chris Newton, SVP Galapagos Services and Managing Director of BioFocus.

Dr. Newton continued, “This project plays to BioFocus historic strengths and the expanding breadth and depth of this partnership is testament to a tried and trusted relationship.”

Kazuhito Kawabata, Ph.D., Member of the Board of Directors, Executive Officer and Executive Director, Discovery and Research of Ono commented: “We have the highest regard for the BioFocus’ comprehensive drug discovery platform. This collaboration will strengthen Ono’s drug discovery capability in the field of CNS disorders with significant unmet medical needs and we are expecting that innovative drugs will be created through this collaboration.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Galapagos Initiates a Phase 2a Study with GLPG1690
Company has announced that it has initiated a phase 2a study with GLPG1690 in idiopathic pulmonary fibrosis patients.
Thursday, April 07, 2016
Galapagos Appoints David Smith as CEO of Service Division
David Smith was CFO of Galapagos for two years.
Wednesday, August 21, 2013
Galapagos Starts Phase 2A Study with GLPG0974 in Ulcerative Colitis
Study will deliver topline results early 2014.
Tuesday, April 23, 2013
Galapagos Discovers Novel Candidate Drug to Treat Breast Cancer
GLPG1790 has high efficacy against triple-negative breast cancer.
Monday, April 22, 2013
Galapagos Acquires Cangenix
Galapagos to add structure-based drug discovery to the Argenta service offering.
Wednesday, January 16, 2013
Ono and Galapagos Sign an Additional Target Discovery Agreement
Collaboration agreement on discovering novel targets in the field of allergic diseases.
Wednesday, May 30, 2012
Galapagos Delivers Candidate Drug in GSK Alliance
Galapagos NV has announced that it delivered a fourth candidate drug in its arthritis alliance with GlaxoSmithKline (GSK) in December 2010. This achievement triggered a €6.7 million milestone payment to Galapagos, which was included in 2010 revenues.
Friday, March 04, 2011
Galapagos Receives €2.7 Million Grant for Antiviral Drug Discovery
The antiviral programs focus on blocking the activity of a protein in the human body that is essential for a number of important pathogenic viruses to carry out their own reproduction.
Friday, February 18, 2011
Galapagos Receives €4 Million in Milestones from Servier
Servier and Galapagos announced their alliance to develop new medicines for the treatment of osteoarthritis.
Friday, February 18, 2011
Galapagos Receives €7.4 M Milestone in Arthritis Alliance with GlaxoSmithKline
Galapagos completed first-in-human trials for GLPG0555 and initiates clinical Phase I development for a second candidate drug, GLPG0778.
Thursday, January 13, 2011
Galapagos Receives €3.7 Million Grant for Cystic Fibrosis Program
The three-year project focuses on Galapagos' cystic fibrosis program based on novel drug targets to deliver a pre-clinical candidate.
Monday, November 01, 2010
Galapagos' Affiliate BioFocus Extends Collaboration with Chiesi
BioFocus to provide medicinal chemistry and biology services, with an additional option for ADME services, for a Chiesi therapeutic program.
Thursday, October 14, 2010
Galapagos' Affiliate Argenta and Janssen Enter in Integrated Cancer Drug Discovery Service Agreement
Initial phase includes research funding and success-based milestones over five years.
Saturday, October 09, 2010
Galapagos Initiates Phase I Study for JAK inhibitor GLPG0634
Company announces the acquisition of full rights to the compound from GSK.
Monday, August 09, 2010
Galapagos and University of Bristol Enter Drug Discovery Collaboration in Chronic Pain
BioFocus will provide hit-to-lead and lead optimization services for a €3.3 million drug discovery program at the University of Bristol.
Friday, July 16, 2010
Scientific News
Turning Skin Cells into Heart, Brain Cells
In a major breakthrough, scientists at the Gladstone Institutes transformed skin cells into heart cells and brain cells using a combination of chemicals.
Experimental Drug Cancels Effect from Key Intellectual Disability Gene
A University of Wisconsin—Madison researcher who studies the most common genetic intellectual disability has used an experimental drug to reverse — in mice — damage from the mutation that causes the syndrome.
Doubling Down on Dengue
HMS researchers have discovered two ways a compound blocks dengue virus.
Reprogramming Scorpion Venom
‘Twist of nature’ neutralizes toxin.
Tailoring a Suit for Tumor-Penetrating Cancer Meds
For more than a decade, biomedical researchers have been looking for better ways to deliver cancer-killing medication directly to tumors in the body.
Resurrecting an Abandoned Drug
Previously discarded drug shows promise in helping human cells in a lab dish fight off two different viruses.
Safer, Cheaper, Greener and More Efficient System for Organic Synthesis
The new medium not only supports organic synthesis it also produces considerably higher yields of product than pure organic solvents.
Fighting Prostate Cancer
Identifying the most promising compounds which can be used as medications for prostate cancer.
Collaboration to Develop Cancer Therapeutics
Major license agreement with Merck, enabled by Blavatnik Biomedical Accelerator, aims to develop therapy for most common form of acute leukemia.
Faster UVA Molecular Analysis Technology
There are people in the world – chemical engineers, astronomers, national defense scientists investigating an explosion – who need to know just what something is made of, down to the molecular level.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!